本帖最后由 老马 于 2012-1-13 21:20 编辑
8 C; y7 \/ z0 O/ ?/ D
' U1 _" l( o4 G0 ?) g3 a9 A+ V3 m爱必妥和阿瓦斯丁的比较9 ?! w% j ]" M' \
" ~& u S0 e2 D/ W* H$ Yhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
7 I8 q! ~* a! f G: _6 M
3 E K' h( j8 t4 z. k' e9 s
9 h- j" Z* N0 p% {# `& U: e( v
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
Y' Y* h1 D% @& i. B; ^==================================================9 n7 ~4 A5 s9 {! I) U8 F0 T: ]
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), B: o# q# ]. A4 F. N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
8 i D9 B$ g1 U5 O D& \Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# g5 e( ^4 d7 W$ R I
|